<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560166</url>
  </required_header>
  <id_info>
    <org_study_id>203</org_study_id>
    <nct_id>NCT04560166</nct_id>
  </id_info>
  <brief_title>Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma</brief_title>
  <official_title>Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination With Irinotecan and Temozolomide in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Y-mAbs Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Y-mAbs Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An International, Single-Arm, Multicenter Phase 2 Trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, single-arm, multicenter phase 2 trial, in patients ≥ 12 months of&#xD;
      age with high-risk NB with primary refractory disease or in first relapse. Patients will&#xD;
      receive naxitamab + GM-CSF + irinotecan/temozolomide. The Follow-Up period ends 2 years after&#xD;
      End of Treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>84 days</time_frame>
    <description>The proportion of patients obtaining a centrally assessed complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR after 2 cycles</measure>
    <time_frame>42 days</time_frame>
    <description>The proportion of patients obtaining a centrally assessed CR or PR according to the INRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>2 years</time_frame>
    <description>The time from first centrally assessed overall response (OR) (CR or PR according to the INRC) to PD or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>84 days</time_frame>
    <description>the proportion of patients obtaining a centrally assessed CR according to the INRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent therapy</measure>
    <time_frame>3 years</time_frame>
    <description>the time from initiation of IMP treatment until death or start of new anti-cancer treatment (prohibited as per protocol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>the time from enrollment until progressive disease or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients alive and with no PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 2 years</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of patients alive and with no PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>the time from enrollment until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>the time from enrollment until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 2 years</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of patients alive</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Neuroblastoma Recurrent</condition>
  <arm_group>
    <arm_group_label>Naxitamab and GM-CSF in combination with irinotecan and temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A treatment cycle is 21 days. The patients will receive irinotecan 50 mg/m2/day IV and temozolomide 100 mg/m2/day orally (both on Days 1-5) in combination with naxitamab 2.25 mg/kg/day IV (Days 2, 4, 8 and 10) (total 9 mg/kg per cycle), and GM-CSF 250 ug/m2/day sc, (Days 6-10).&#xD;
Patients will receive up to 18 IT cycles after enrollment. Naxitamab and GM-CSF will be given for at least 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naxitamab and GM-CSF in combination with irinotecan and temozolomide</intervention_name>
    <description>Irinotecan, solution for infusion (20 mg/mL)&#xD;
Temozolomide, capsules (5 mg, 20 mg and 100 mg)&#xD;
The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)&#xD;
Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)</description>
    <arm_group_label>Naxitamab and GM-CSF in combination with irinotecan and temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neuroblastoma (NB)&#xD;
&#xD;
          -  Documented high-risk disease&#xD;
&#xD;
          -  Receipt of Standard of Care (SoC) frontline induction/consolidation therapy (including&#xD;
             surgery, chemotherapy, ASCT, MIBG, radiotherapy, immunotherapy, or retinoids)&#xD;
&#xD;
          -  Active disease despite previous aggressive multi-drug chemotherapy, defined as one of&#xD;
             the following:&#xD;
&#xD;
               -  verified first progression during multi-drug frontline treatment or&#xD;
&#xD;
               -  verified first episode of relapse, defined as recurrence after response to&#xD;
                  frontline treatment, or&#xD;
&#xD;
               -  verified first designation of refractory disease, defined as persistent&#xD;
                  metastatic disease (SD or minor response by INRC and MIBG curie score ≥3)&#xD;
                  detected at conclusion of at least 4 cycles of multi-drug induction chemotherapy&#xD;
                  on or according to a high-risk NB treatment protocol as defined above&#xD;
&#xD;
          -  The patients must have one of the following (locally assessed) obtained within 3 weeks&#xD;
             prior to enrollment and at least 10 calendar days after end of any prior anti-cancer&#xD;
             treatment:&#xD;
&#xD;
               -  Measurable tumor on CT/MRI scan that is MIBG-avid or demonstrates increased FDG&#xD;
                  uptake on PET scan&#xD;
&#xD;
               -  MIBG (Metaiodobenzylguanidine) scan with positive uptake at a minimum of one&#xD;
                  site. This site must represent disease recurrence after completion of therapy,&#xD;
                  progressive disease on therapy, or refractory disease during induction&#xD;
&#xD;
          -  Age ≥ 12 months at enrollment&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myelodysplastic syndrome or any malignancy other than NB&#xD;
&#xD;
          -  Any systemic anti-cancer therapy within 3 weeks&#xD;
&#xD;
          -  Autologous stem cell transplant (ASCT) within 6 weeks prior to enrollment or ongoing&#xD;
             toxicity due to the stem cell transplant at the discretion of the investigator&#xD;
&#xD;
          -  Therapeutic 131I-MIBG within 6 weeks prior to enrollment&#xD;
&#xD;
          -  Radiotherapy (RT) within 4 weeks prior to enrollment at any lesion site that will be&#xD;
             identified as a target lesion to measure tumor response&#xD;
&#xD;
          -  Prior treatment with anti-GD2 if the patient experienced Progressive Disease (PD)&#xD;
             while on anti-GD2 treatment&#xD;
&#xD;
          -  Receipt of second line chemotherapy after designation of primary refractory disease or&#xD;
             first relapse or PD&#xD;
&#xD;
          -  NB in Bone Marrow (BM) only&#xD;
&#xD;
          -  NB in the Central Nervous System (CNS) or leptomeningeal disease within 6 months prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Performance status of &lt; 50% as per the Lansky scale (patients less than 16 years of&#xD;
             age) or Karnofsky scale (for patients aged 16 years or older)&#xD;
&#xD;
          -  Life expectancy of less than 6 months&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% by echocardiography&#xD;
&#xD;
          -  Inadequate pulmonary function&#xD;
&#xD;
          -  Diarrhea Grade ≥ 2&#xD;
&#xD;
          -  Treatment with long-acting myeloid growth factor within 14 days or short-acting&#xD;
             myeloid growth factor within 7 days prior to first dose of GM-CSF&#xD;
&#xD;
          -  Receipt of immunosuppressive treatment (local steroids excluded) within 4 weeks prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Life threatening infection(s)&#xD;
&#xD;
          -  Uncontrolled seizure disorders despite anticonvulsant therapy (defined as a seizure&#xD;
             event within 3 months prior to enrollment)&#xD;
&#xD;
          -  Treatment with enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or&#xD;
             carbamazepine for at least 7 days prior to enrollment&#xD;
&#xD;
          -  Concomitant use with St John's wort&#xD;
&#xD;
          -  Allogeneic hematopoietic stem cell transplantation (allo-SCT) or&#xD;
             donor-lymphocyte-infusion (defined as any kind of active allogeneic lymphocyte&#xD;
             suspension)&#xD;
&#xD;
          -  Treatment with Hematopoietic Progenitor Cell (HPC) boost within 2 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  History of allergy or known hypersensitivity to GM-CSF, yeast-derived products, or any&#xD;
             component of GM-CSF, naxitamab, irinotecan or temozolomide&#xD;
&#xD;
          -  History of anaphylactic reactions CTCAE Grade 4 related to prior anti-GD2 antibody&#xD;
             therapy&#xD;
&#xD;
          -  Unacceptable hematological status at screening, defined as one of the following:&#xD;
&#xD;
               -  Hemoglobin &lt;5.0 mmol/L (&lt;8 g/dL)&#xD;
&#xD;
               -  White blood cell count &lt;1000/µL&#xD;
&#xD;
               -  Absolute neutrophil count &lt;750/µL&#xD;
&#xD;
               -  Platelet count &lt; 75,000/µL&#xD;
&#xD;
          -  Unacceptable liver function at screening, defined as one of the following:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;5 times&#xD;
                  upper normal limit (UNL)&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 x UNL&#xD;
&#xD;
          -  Unacceptable kidney function at screening, defined as estimated glomerular filtration&#xD;
             rate (eGFR) &lt;60 mL/min/1.73 m2 calculated by the 2009 revised Bedside Schwartz&#xD;
             Equation&#xD;
&#xD;
          -  Inability to comply with protocol&#xD;
&#xD;
          -  Significant intercurrent illness (any ongoing serious medical problem unrelated to&#xD;
             cancer or its treatment) that is not covered by the detailed exclusion criteria and&#xD;
             that is expected to interfere with the action of trial agents or to significantly&#xD;
             increase the severity of the toxicities experienced from trial treatment&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant, breast feeding, intend to become&#xD;
             pregnant, or are not using adequate contraceptive methods or males who are not using&#xD;
             adequate contraceptive methods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joris Wilms</last_name>
    <phone>+4570261414</phone>
    <email>clinicaltrials@ymabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hong Kong Children's Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raisa Gorbacheva Memorial Institute of Children's Hematology and Transplantation Bone marrow Transplant Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre - Mt Elizabeth Novena Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

